Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:2257-2262
Published online before print October 14, 2004, doi: 10.1161/01.ATV.0000147406.00871.b3
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
24/12/2257    most recent
01.ATV.0000147406.00871.b3v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kartikasari, A. E.R.
Right arrow Articles by Marx, J. J.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kartikasari, A. E.R.
Right arrow Articles by Marx, J. J.M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*IRON
Related Collections
Right arrow Pathophysiology
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:2257.)
© 2004 American Heart Association, Inc.

Vascular Biology

Intracellular Labile Iron Modulates Adhesion of Human Monocytes to Human Endothelial Cells

Apriliana E.R. Kartikasari; Niki A. Georgiou; Frank L.J. Visseren; Henny van Kats-Renaud; B. Sweder van Asbeck; Joannes J.M. Marx

From the Eijkman-Winkler Center for Medical Microbiology (A.E.R.K., N.A.G., F.L.J.V., H.v.K.-R., B.S.v.A., J.J.M.M.), Infectious Diseases, and Inflammation and Eijkman Graduate School for Immunology and Infectious Diseases, and the Departments of Vascular Medicine (F.L.J.V.) and Internal Medicine (B.S.v.A.), University Medical Center Utrecht, The Netherlands.

Correspondence Prof Joannes J.M. Marx, MD, PhD, Eijkman-Winkler Center for Medical Microbiology, Infectious Diseases, and Inflammation, University Medical Center Utrecht, 100 Heidelberglaan G04.614, 3584CX Utrecht, The Netherlands. Email jmarx{at}azu.nl


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Objective— Elevated iron stores and high plasma iron concentration have been linked to an increased risk of atherosclerosis. Iron may thereby affect the interaction of monocytes to endothelium, an initial event in the formation of atherosclerotic plaques.

Methods and Results— Addition of 10 µmol/L non–transferrin-bound iron to the incubation medium caused a 2-fold increase in monocyte adhesion to human umbilical vein endothelial cells (HUVECs). A concordant increase in the expression of the following adhesion molecules was observed: vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and endothelial selectin on HUVECs as well as very late antigen-4, and lymphocyte function–associated antigen-1 on monocytes. The inclusion of either deferiprone or salicylaldehyde isonicotinoylhydrazone counteracted these effects. Intracellular iron chelation by deferoxamine was completed only after 10 hours of incubation, shown by reversal of iron-quenched intracellular calcein signal, and concurrently the effects of iron were blunted. The membrane-impermeable chelator, diethylenetriamine pentaaceticacid, failed to negate iron effects, even after 48 hours of treatment. Furthermore, only membrane-permeable superoxide or hydroxyl radical scavengers were capable of preventing HUVEC activation by iron.

Conclusions— Non–transferrin-bound iron increases the level of intracellular labile iron, which promotes monocyte recruitment to endothelium and may thereby contribute to the pathogenesis of atherosclerosis. Iron-induced adhesion molecule expression was observed, and this event may involve the production of oxygen radicals.

An increase in the level of intracellular labile iron induced monocyte adhesion to endothelium, an initial event in atherosclerotic plaque formation. A concordant increase in the cell adhesion molecule expression was observed. Furthermore, only inclusion of membrane-permeable iron chelators and radical scavengers resulted in a complete inhibition of these effects of iron.


Key Words: iron • atherosclerosis • monocytes • endothelium • adhesion molecules


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Atherosclerosis has been associated with several important environmental and genetic risk factors. It is characterized by inflammatory changes leading to plaque formation and, furthermore, to plaque rupture and arterial thrombosis. Transendothelial migration of leukocytes is a fundamental inflammatory mechanism in atherogenesis.1 This process is partly mediated by the interaction between endothelial adhesion molecules and their ligands on monocytes.

Elevated concentrations of adhesion molecules have been observed in human atherosclerotic plaques, including 2 members of the immunoglobulin superfamily of adhesion receptors, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), as well as a member of the selectin family, endothelial selectin (E-Selectin). Moreover, a significant correlation has been found between the degree of macrophage infiltration and endothelial ICAM-1, VCAM-1, and E-selectin expression in atherosclerotic lesions.2

The infiltration of leukocytes consists of consecutive adhesion-mediated events. The first step of adhesion involves binding of selectins to carbohydrate ligands that triggers tethering of the leukocytes to the activated endothelium along the vessel wall. Arrest and firm adhesion of the leukocytes on activated endothelial cells occur depending on the activation of the integrins very late antigen-4 (VLA-4) and lymphocyte function–associated antigen-1 (LFA-1).3

In 1981, Sullivan4 suggested that iron depletion may protect against ischemic heart disease. Many epidemiological studies have tested this iron hypothesis. Some showed that the level of body iron stores, as measured by serum ferritin concentration, is positively correlated to the incidence of cardiovascular diseases.5–11 However, others have yielded conflicting results.12–18

Recent studies have demonstrated that carriers of the HFE mutant gene C282Y, responsible for autosomal recessive hereditary hemochromatosis, have a significantly higher plasma concentration of non–transferrin-bound iron (NTBI) than the normal population19 and are at an increased risk of cardiovascular-related death or myocardial infarction.20–22 However, some other studies failed to reveal an increased risk of atherosclerosis in population carrying HFE mutant gene.23–27 A positive association between frequent blood donations and reduced risk of myocardial infarction has been reported,28–30 presumably caused by iron depletion. However, in one study, iron depletion caused by blood donation did not appear to reduce the risk of cardiovascular diseases.31 Additionally, a community-based prospective cohort study showed that heme iron intake was significantly correlated with total iron stores and the risk of cardiovascular diseases.32–35

Given the potential role of iron in atherosclerosis, we investigated the effects of iron-rich and iron-withholding conditions in the course of human monocyte adhesion to human umbilical vein endothelial cells (HUVECs) as one of the earliest events of atherosclerotic plaque formation. Several iron chelators of different cell-membrane permeability were used to investigate the involvement of extracellular and intracellular labile iron in this process. The involvement of toxic oxygen species formed through iron-catalyzed Fenton reaction was also investigated.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
HUVEC Isolation and Culture
HUVECs were isolated and cultured as described by Jaffe et al36 with minor modifications (for details, please see the online Methods, available at http://atvb.ahajournals.org).

Monocyte Isolation
Two different methods of monocyte isolation were used depending on the amount of cells needed (see online Methods): the countercurrent centrifugal elutriation37 and the negative immunoselection monocyte isolation kit (Miltenyi Biotec).

Preparation of Iron Solutions and Chelator-Bound Iron
Two different iron compounds were used in this study. A 10-mmol/L Fe(II)ammoniumsulfate (Merck) solution was made by dissolving the iron crystals in distilled water at room temperature. A 10-mmol/L Fe(III)citrate (Sigma; 1:6 iron-citrate molar ratio) solution was made by dissolving the iron crystals in distilled water at 56°C for 30 minutes. Iron solutions were always freshly prepared and filter-sterilized before use. Fe(III)citrate was used, because the majority of NTBI is found in a complex form of Fe(III) to citrate, as shown by NMR spectroscopy of serum from patients with iron overload.38

Chelator stocks were prepared as follows: 10 mmol/L deferoxamine (DF; Novartis) in PBS, 30 mmol/L deferiprone (L1; Duchefa Biochemie) in PBS, 10 mmol/L diethylenetriamine pentaaceticacid (DTPA; Sigma) in PBS, and 20 mmol/L salicylaldehyde isonicotinoylhydrazone (SIH)39 in dimethylsulfoxide. Preparation of fully-saturated chelator-bound iron solutions was done a few minutes before such solutions were added to the incubation medium (see online Methods).

The detectable iron from the endothelial basal medium-2, which is the medium used to perform all of the experiments involving HUVECs, was measured by Vitros 950 Chemistry System (Ortho-Clinical Diagnostics; see online Methods). With no external iron addition, the baseline iron level was counted to be {approx}0.36 µmol/L. In all experiments, plastic materials with low affinity for iron were used. The contaminant iron level in the working containers and the basal cell culture growth medium is relatively low compared with the iron concentrations used in this study.

In Vitro Cytoadherence Assay
Monocytes and HUVECs were pretreated with different combinations of compounds of interest before the assay. After treatment, monocytes were labeled with 2',7'-Bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethylester (BCECF-AM, Molecular Probes). The cytoadherence of monocytes (25x104 cells per well) to HUVEC monolayer (5x104 cells per well) was performed in a 96-well plate for 30 minutes at 37°C with gentle agitation. Fluorescence was read using a filter pair for excitation at 485 nm and emission at 530 nm in a CytoFluor II fluorescence microplate reader (Perseptive Biosystems). This value represented total fluorescing monocytes added to each well. After thorough washing, fluorescence was again measured, and the value represented the remaining monocytes firmly attached to the HUVEC monolayer. The percentage of adhesion was defined as the value of remaining fluorescence divided by the value of total fluorescence multiplied by 100.

Fluorescence-Activated Cell Sorting
After treatment with various compounds of interest, HUVECs or monocytes were incubated with fluorescence-labeled monoclonal antibodies against the adhesion molecules of interest. The level of the adhesion molecule expression on these cells was then analyzed by the FACS analysis using a Becton Dickinson FACScan (see online Methods).

3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl Tetrazolium Bromide (MTT) Viability Assay for HUVECs and Trypan Blue Exclusion Test for Monocytes
Cellular viability of HUVECs was monitored by the MTT (Sigma) method,40 whereas cellular viability of monocytes after the various compound incubations was monitored using the trypan blue exclusion test (see online Methods).

Calcein-AM Assay
The membrane permeability of iron chelators was followed by the calcein-AM assay41 (see online Methods). One hundred µmol/L of Fe(III)citrate was loaded to confluent HUVECs for 1 hour before the addition of 0.125 µmol/L calcein-AM (30 minutes at 37°C). After the signal was stabilized, the chelator of interest was added. This fluorescence signal (excitation=485 nm; emission=530 nm) was followed for a specified time period. Reversal of the quenched calcein signal by addition of a chelator gives an indication as to the membrane permeability of the chelator at a specific time point.

Data Analysis
Results are expressed as means+SEM. Differences in quantitative measures were tested for significance using the unpaired 2-tailed Student t test.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
Cell Viability
After 48 hours of incubation with up to 300 µmol/L Fe(II)ammoniumsulfate or Fe(III)citrate, the viability of HUVECs was >95% as determined by the MTT assay (not shown). TC50 of DF, L1, SIH, and DTPA were also determined. TC50 increased when chelators were bound to iron (Table I, available online at http://atvb.ahajournals.org) indicating their specificity for iron. The MTT assay was also performed to assure that the concentrations of compounds of interest used in all experiments retained 95% cell viability. Monocytes were >95% viable after treatment with <100 µmol/L Fe(II)ammoniumsulfate or Fe(III)citrate for 3 hours shown by the trypan blue exclusion test (not shown).

Iron Modulates Human Monocyte Adhesion to Human Vascular Endothelium
The extent of monocyte adhesion to the endothelium was determined by an in vitro cytoadherence assay. Confluent HUVECs were incubated for 5 hours, whereas monocytes were incubated for 1 hour with Fe(II)ammoniumsulfate. Compared with untreated cells, more iron-treated monocytes adhered to HUVECs and, similarly, more monocytes adhered to iron-treated HUVECs (Figure 1A). A 2-fold increase in adhesion was observed when both endothelial cells and monocytes were pretreated with iron. When HUVECs were incubated with either DF-, L1-, or SIH-saturated iron, this phenomenon was no longer observed (Figure 1B), indicating that the increase in monocyte adhesion to HUVECs was attributed to the presence of iron, the level of which was modulated by external addition of NTBI.



View larger version (18K):
[in this window]
[in a new window]
  		Figure 1. Effects of iron (A) and chelator-bound iron (B) on monocyte adhesion to endothelium (mean±SEM; n=6; *different from control, P<0.05). Source of iron was Fe(II)ammoniumsulfate with incubation time of 5 hours on HUVECs (A and B) and 1 hour on monocytes (A).

Effects of Iron on VCAM-1, ICAM-1, and E-Selectin Expression on HUVECs and the Counter Receptors: VLA-4 and LFA-1 on Monocytes
Incubation of endothelial cells for 48 hours with increasing concentrations of Fe(II)ammoniumsulfate or Fe(III)citrate increased VCAM-1, ICAM-1, and E-selectin expression on HUVECs as observed by the FACS analysis (Figure 2 A through 2D). No difference was seen between Fe(II)ammoniumsulfate and Fe(III)citrate, which may be because of the long incubation time under conditions that promote oxidation of Fe(II). The enhancement of VCAM-1 expression is much more pronounced than ICAM-1 or E-selectin with lower dosage of iron (ie, 1 to 20 µmol/L; Figure 2A). The upregulation of all 3 adhesion molecule expressions was more marked as higher dosage of iron (Figure 2A through 2C) or longer incubation with iron (Figure 3 A and 3B) was applied. These suggest an iron-induced process as dose- and time-dependent, causing an augmentation of HUVEC activation as more iron accumulates intracellularly. Saturating iron with either DF, L1, or SIH completely blunted the effects of iron in VCAM-1 expression (Figure 3C) as well as ICAM-1 and E-selectin (not shown), confirming the involvement of iron in this process.



View larger version (25K):
[in this window]
[in a new window]
  		Figure 2. Effects of iron on the expression of endothelial adhesion molecules: VCAM-1 (A), ICAM-1 (B), and E-selectin (C) after 48 hours incubation (mean±SEM; n=6; *different from control, P<0.001). The mean fluorescence from monoclonal antibody against adhesion molecules, analyzed by FACS, correlates to the expression of adhesion molecules on the cell surface (illustrated in D).



View larger version (39K):
[in this window]
[in a new window]
  		Figure 3. The expression of adhesion molecules on HUVECs or monocytes after treatment with iron or chelator-bound iron. VCAM-1 expression (mean±SEM; n=3) was lower in 8 hours (A) compared to 48 hours (B) 100 µmol/L Fe(III)citrate-treated HUVEC (P<0.001; n=6). Forty-five hours (B) but not 5 hours (A) of DF treatment was enough to negate iron activation on HUVECs. C, VCAM-1 expression on HUVECs after 48 hours of treatment with iron or chelator-bound iron freshly prepared before being added to the incubation medium (mean±SEM; n=3; *different from control, P<0.001). #Iron was preloaded to HUVECs for 3 hours before a chelator was added for 45 hours. Monocyte surface integrin expression was altered (D) after 1-hour incubation with iron but remained the same as control after 1-hour incubation with DF-bound iron freshly prepared before being added to the incubation medium (mean±SEM; n=3; *different from control, P<0.05).

Subsequent increase in the expression of VLA-4 and LFA-1 was observed on monocytes after 1 hour of 10 µmol/L Fe(III)citrate treatment, suggesting that monocyte activation was attributed to the presence of iron. Incubation with DF-bound iron resulted only in the basal level of expression of these 2 integrins, confirming the involvement of iron in monocyte activation (Figure 3D).

Intracellular Iron Involved in Iron-Induced Monocyte Adhesion to Endothelium
Using the calcein-AM quenching test, the cell-membrane permeability of 4 different chelators was assayed (Figure 4A). L1 and SIH were highly permeant, as after a 2-hour incubation period these 2 chelators could considerably restore the quenched calcein signal. In contrast, DTPA was ineffective at restoring the signal, confirming its membrane impermeability. DF, on the other hand, slowly dequenched calcein signal. Ten hours were needed for 100 µmol/L DF to completely restore the signal previously quenched by 100 µmol/L Fe(III)citrate (Figure 4B). However, <5 hours were required for 10 µmol/L DF to restore the signal quenched by 10 µmol/L Fe(III)citrate.



View larger version (26K):
[in this window]
[in a new window]
  		Figure 4. The calcein-AM assay for assessing the membrane permeability of iron chelators. One hundred percent of fluorescence means no calcein quenching by iron; <100% shows calcein quenching. The time needed for the chelators to enter HUVECs is illustrated as the time to dequench calcein signal after iron treatment (A; mean; n=3). B, Completion of intracellular iron chelation by DF after 10 hours of incubation (mean; n=3).

Treatment with DF for 5 hours on HUVECs pretreated with 100 µmol/L Fe(III)citrate did not fully counteract iron-induced VCAM-1 expression (Figure 3A). After 45 hours of DF treatment (Figure 3B), HUVECs expressed the same amount of VCAM-1 as the non–iron-treated cells. The results suggest that chelation of intracellular iron was necessary to counteract the effects of iron.

A similar experiment was also done using L1 and DTPA (Figure 3C). L1 easily penetrated the endothelial cells and was also capable of counteracting the effects of iron on HUVECs. DTPA, on the other hand, was ineffective. These results confirm the need of chelating intracellular iron to prevent HUVEC activation by iron.

Involvement of Oxygen Radicals in Iron-Promoted Cytoadherence
Promotion of monocyte adhesion to endothelium by iron was no longer observed when HUVECs were coincubated with 5 mmol/L dimethylthiourea (DMTU), a scavenger for both H2O2 and OH. Incubation of confluent HUVECs with H2O2 alone did not induce further monocyte adhesion to endothelium (Figure 5A). These results suggest that iron may produce its effects through the production of reactive oxygen species other than H2O2.



View larger version (25K):
[in this window]
[in a new window]
  		Figure 5. Effects of radical scavengers on iron-activated HUVECs, shown by the cytoadherence assay of monocytes to HUVECs (A; mean±SEM; n=5; *different from control, P<0.05) and VCAM-1 expression on HUVECs (B; mean±SEM; n=6; #different from control, P<0.001).

Furthermore, a range of both membrane-permeable and -impermeable scavengers with specific scavenging activity for either O2–, H2O2, or OH· was tested to reveal their involvement in iron-promoted endothelial adhesion molecule expression (Figure 5B). Besides DMTU (H2O2 and OH· scavenger), only thiourea (OH· scavenger) and tempol (O2– scavenger) could counteract the effects of iron on VCAM-1 upregulation. Neither membrane-impermeable scavengers, superoxide dismutase (O2– scavenger), catalase (H2O2 scavenger), and mannitol (OH· scavenger), a membrane-permeable H2O2 scavenger (pyruvate), nor urea (a compound control for DMTU and thiourea) could neutralize the effects of iron. H2O2 alone could not increase the basal expression of VCAM-1. H2O2 in combination with iron gave the same level of VCAM-1 expression as iron alone. Similar results from this set of experiments were observed in endothelial ICAM-1 and E-selectin expression (not shown). These results suggest that iron activates HUVECs through the production of either O2– or OH· or both within the cells.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
Monocyte migration across the endothelium is an initial pathogenic event of atherosclerosis.1 Iron in vitro has been shown to upregulate interleukin-6 production by HUVECs,42 whereas iron chelators inhibit the tumor necrosis factor-{alpha}–mediated upregulation of endothelial adhesion molecules.43,44

In iron overload diseases with 100% transferrin saturation, such as hemochromatosis, a labile form of iron may exist. Furthermore, it is believed that labile iron may also be present in response to other triggers disturbing iron homeostasis. NTBI can be detected in plasma and is bound to ligands with substantially less affinity than transferrin, such as citrate38 and albumin. NTBI is capable of freely entering the cell with no feedback-regulated process.45 Intracellular iron may only be bound to low-molecular weight ligands, catalytically active and capable of initiating free radical reactions.46 The expansion of intracellular labile iron, which may parallel that of NTBI, may lead to cell toxicity.

In this study, we used Fe(II)ammoniumsulfate and Fe(III)citrate as the source of free iron in the incubation medium to investigate the effects of intracellular catalytically-active iron in monocyte interaction to endothelium. Ten µmol/L of iron could directly activate and stimulate the expression of adhesion molecules on both HUVECs and monocytes as well as promote monocyte adhesion to endothelial cells. No enhancement in the adhesion molecule expression and the cytoadherence was observed when chelator-bound iron was added, confirming the involvement of iron in this process.

Proinflammatory cytokines have been shown to be involved in the development of atherosclerosis.1 These cytokines induce iron uptake by monocytes and macrophages.47 Subsequently, our results show an upregulation of monocyte integrin expression due to the presence of labile iron, suggesting that iron may enhance monocyte activation.

L1 and SIH nullified the effect of iron on HUVECs, most probably by chelating intracellular iron. In contrast, DTPA gave no counteracting effect once iron had accumulated. The effectiveness of DF to negate iron effects was time- and concentration-dependent: the higher the level of intracellular iron, the longer the time needed for DF to counteract the effect of iron. This may be because of the route through which DF enters the cells.48 DF enters intact cells by endocytosis. It slowly accumulates in the endosome-lysosome complex, and after longer periods of exposure it is capable of removing intracellular iron. This suggests chelation of intracellular labile iron as an effective way to prevent iron-induced cell activation.

In HUVECs, iron-induced adhesion molecule expression was in a concentration- (0 to 100 µmol/L) and time-dependent manner. Resting levels of iron in the cultured HUVECs might be 10-fold less than in freshly isolated HUVECs,49,50 and {approx}1/3 of the amount of NTBI in the loading medium may enter the cells.49 Because NTBI is generally in the range of 1 to 20 µmol/L,51 the results in this study may not only be significant for various conditions of iron overload but also meaningful for normal physiological situations, as an increase in intracellular labile iron in vivo may incline adhesion. This suggests that any condition that disturbs iron homeostasis, even in normal population, may increase the risk for developing atherosclerosis. Furthermore, this study implies that stimulation of adhesion in vivo may reach its lowest point in a state of iron deficiency, which may be protective against atherosclerosis but may also lead to a defective immune function.

Antioxidants have been shown to protect against endothelial dysfunction associated with atherosclerosis,52 whereas iron chelators were capable of preventing hydroxyl radical damage.53 Reactive oxygen species, possibly formed through iron-catalyzed Fenton reaction, may be involved in atherogenesis. In our study, DMTU inhibited iron-induced monocyte adherence to HUVECs. Furthermore, only DMTU and 2 other membrane-permeable scavengers, tempol and thiourea, were able to inhibit iron-induced endothelial adhesion molecule expression, suggesting that O2– and OH· are involved in the process of iron-induced monocyte recruitment to HUVECs.

In conclusion, additional NTBI increases the level of intracellular labile iron. This labile iron may play a role as an independent risk factor in atherosclerosis by promoting monocyte recruitment to endothelium. It modulates the expression of cell adhesion molecules on HUVECs as well as the integrins on monocytes. Iron chelators commonly used for the treatment of secondary iron overload can effectively prevent these iron-mediated events. Furthermore, intracellular labile iron may promote its effect through the production of oxygen radicals, particularly superoxide and hydroxyl radicals.


*    Acknowledgments
 
This work was supported by European Commission, QLRT-2001-0044 (http://www.nutrientirontoxicity.nl). We thank J.J.M. Bouwman (Diakonessen Hospital, Utrecht, the Netherlands) for providing the umbilical cords and Prof P. Ponka (McGill University, Montreal, Canada) for providing the iron chelator SIH.

Received June 14, 2004; accepted September 9, 2004.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233–241.[CrossRef][Medline] [Order article via Infotrieve]
  2. O’Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation. 1996; 93: 672–682.[Abstract/Free Full Text]
  3. Ronald JA, Ionescu CV, Rogers KA, Sandig M. Differential regulation of transendothelial migration of THP-1 cells by ICAM-1/LFA-1 and VCAM-1/VLA-4. J Leukoc Biol. 2001; 70: 601–609.[Abstract/Free Full Text]
  4. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981; 1: 1293–1294.[Medline] [Order article via Infotrieve]
  5. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992; 86: 803–811.[Abstract/Free Full Text]
  6. Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, Spogler F, Jarosch E, Oberhollenzer F, Willeit J. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study. Arterioscler Thromb. 1994; 14: 1625–1630.[Abstract/Free Full Text]
  7. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997; 96: 3300–3307.[Abstract/Free Full Text]
  8. Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation. 1998; 97: 1461–1466.[Abstract/Free Full Text]
  9. Klipstein-Grobusch K, Koster JF, Grobbee DE, Lindemans J, Boeing H, Hofman A, Witteman JC. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999; 69: 1231–1236.[Abstract/Free Full Text]
  10. Haidari M, Javadi E, Sanati A, Hajilooi M, Ghanbili J. Association of increased ferritin with premature coronary stenosis in men. Clin Chem. 2001; 47: 1666–1672.[Abstract/Free Full Text]
  11. Wolff B, Volzke H, Ludemann J, Robinson D, Vogelgesang D, Staudt A, Kessler C, Dahm JB, John U, Felix SB. Association between high serum ferritin levels and carotid atherosclerosis in the study of health in Pomerania (SHIP). Stroke. 2004; 35: 453–457[Abstract/Free Full Text]
  12. Manttari M, Manninen V, Huttunen JK, Palosuo T, Ehnholm C, Heinonen OP, Frick MH. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J. 1994; 15: 1599–1603.[Abstract/Free Full Text]
  13. Frey GH, Krider DW. Serum ferritin and myocardial infarct. W V Med J. 1994; 90: 13–15.[Medline] [Order article via Infotrieve]
  14. Solymoss BC, Marcil M, Gilfix BM, Gelinas F, Poitras AM, Campeau L. The place of ferritin among risk factors associated with coronary artery disease. Coron Artery Dis. 1994; 5: 231–235.[Medline] [Order article via Infotrieve]
  15. Moore M, Folsom AR, Barnes RW, Eckfeldt JH. No association between serum ferritin and asymptomatic carotid atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1995; 141: 719–723.[Abstract/Free Full Text]
  16. Eichner JE, Qi H, Moore WE, Schechter E. Iron measures in coronary angiography patients. Atherosclerosis. 1998; 136: 241–245.[CrossRef][Medline] [Order article via Infotrieve]
  17. Sempos CT, Looker AC, Gillum RE, Mcgee DL, Vuong CV, Johnson CL. Serum ferritin and death from all causes and cardiovascular disease: the NHANES II Mortality Study. National Health and Nutrition Examination Study. Ann Epidemiol. 2000; 10: 441–448.[CrossRef][Medline] [Order article via Infotrieve]
  18. Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC. Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol. 2003; 158: 144–149.[Abstract/Free Full Text]
  19. de Valk B, Addicks MA, Gosriwatana I, Lu S, Hider RC, Marx JJ. Non–transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest. 2000; 30: 248–251.[CrossRef][Medline] [Order article via Infotrieve]
  20. Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999; 100: 1268–1273.[Abstract/Free Full Text]
  21. Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation. 1999; 100: 1274–1279.[Abstract/Free Full Text]
  22. Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eckfeldt JH. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2001; 154: 739–746.[CrossRef][Medline] [Order article via Infotrieve]
  23. Hetet G, Elbaz A, Gariepy J, Nicaud V, Arveiler D, Morrison C, Kee F, Evans A, Simon A, Amarenco P, Cambien F, Grandchamp B. Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest. 2001; 31: 382–388.[CrossRef][Medline] [Order article via Infotrieve]
  24. Candore G, Balistreri CR, Lio D, Mantovani V, Colonna-Romano G, Chiappelli M, Tampieri C, Licastro F, Branzi A, Averna M. Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy. Blood Cells Mol Dis. 2003; 31: 57–62.[CrossRef][Medline] [Order article via Infotrieve]
  25. Fox CJ, Cullen DJ, Knuiman MW, Cumpston GN, Divitini ML, Rossi E, Gochee PA, Powell LW, Olynyk JK. Effects of body iron stores and haemochromatosis genotypes on coronary heart disease outcomes in the Busselton health study. J Cardiovasc Risk. 2002; 9: 287–293.[CrossRef][Medline] [Order article via Infotrieve]
  26. Franco RF, Zago MA, Trip MD, ten Cate H, van den EA, Prins MH, Kastelein JJ, Reitsma PH. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br J Haematol. 1998; 102: 1172–1175.[CrossRef][Medline] [Order article via Infotrieve]
  27. Battiloro E, Ombres D, Pascale E, D’Ambrosio E, Verna R, Arca M. Haemochromatosis gene mutations and risk of coronary artery disease. Eur J Hum Genet. 2000; 8: 389–392.[CrossRef][Medline] [Order article via Infotrieve]
  28. Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ. 1997; 314: 793–794.[Free Full Text]
  29. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssonen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol. 1998; 148: 445–451.[Abstract/Free Full Text]
  30. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion. 2002; 42: 1135–1139.[CrossRef][Medline] [Order article via Infotrieve]
  31. Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart disease in men. Circulation. 2001; 103: 52–57.[Abstract/Free Full Text]
  32. Klipstein-Grobusch K, Grobbee DE, den Breeijen JH, Boeing H, Hofman A, Witteman JC. Dietary iron and risk of myocardial infarction in the Rotterdam Study. Am J Epidemiol. 1999; 149: 421–428.[Abstract/Free Full Text]
  33. Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation. 1994; 89: 969–974.[Abstract/Free Full Text]
  34. Tzonou A, Lagiou P, Trichopoulou A, Tsoutsos V, Trichopoulos D. Dietary iron and coronary heart disease risk: a study from Greece. Am J Epidemiol. 1998; 147: 161–166.[Abstract/Free Full Text]
  35. Snowdon DA, Phillips RL, Fraser GE. Meat consumption and fatal ischemic heart disease. Prev Med. 1984; 13: 490–500.[CrossRef][Medline] [Order article via Infotrieve]
  36. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973; 52: 2745–2756.
  37. Wahl LM, Katona IM, Wilder RL, Winter CC, Haraoui B, Scher I, Wahl SM. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis. Cell Immunol. 1984; 85: 373–383.[CrossRef][Medline] [Order article via Infotrieve]
  38. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non–transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem. 1989; 264: 4417–4422.[Abstract/Free Full Text]
  39. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta. 1979; 586: 278–297.[Medline] [Order article via Infotrieve]
  40. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55–63.[CrossRef][Medline] [Order article via Infotrieve]
  41. Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik ZI. Fluorescence analysis of the labile iron pool of mammalian cells. Analytical Biochemistry. 1997; 248: 31–40.[CrossRef][Medline] [Order article via Infotrieve]
  42. Visseren FL, Verkerk MS, van der Bruggen T, Marx JJ, van Asbeck BS, Diepersloot RJ. Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. Eur J Clin Invest. 2002; 32 (suppl 1): 84–90.
  43. Zhang WJ, Frei B. Intracellular metal ion chelators inhibit TNF{alpha}-induced SP-1 activation and adhesion molecule expression in human aortic endothelial cells. Free Radic Biol Med. 2003; 34: 674–682.[CrossRef][Medline] [Order article via Infotrieve]
  44. Koo SW, Casper KA, Otto KB, Gira AK, Swerlick RA. Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells. J Invest Dermatol. 2003; 120: 871–879.[CrossRef][Medline] [Order article via Infotrieve]
  45. Kaplan J, Jordan I, Sturrock A. Regulation of the transferrin-independent iron transport system in cultured cells. J Biol Chem. 1991; 266: 2997–3004.[Abstract/Free Full Text]
  46. Konijn AM, Glickstein H, Vaisman B, Meyron-Holtz EG, Slotki IN, Cabantchik ZI. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood. 1999; 94: 2128–2134.[Abstract/Free Full Text]
  47. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood. 2003; 101: 4148–4154.[Abstract/Free Full Text]
  48. Cable H, Lloyd JB. Cellular uptake and release of two contrasting iron chelators. J Pharm Pharmacol. 1999; 51: 131–134.[CrossRef][Medline] [Order article via Infotrieve]
  49. Sasaki K, Hashida K, Michigami Y, Bannai S, Makino N. Restored vulnerability of cultured endothelial cells to high glucose by iron replenishment. Biochem Biophys Res Commun. 2001; 289: 664–669.[CrossRef][Medline] [Order article via Infotrieve]
  50. Varani J, Dame MK, Gibbs DF, Taylor CG, Weinberg JM, Shayevitz J, Ward PA. Human umbilical vein endothelial cell killing by activated neutrophils. Loss of sensitivity to injury is accompanied by decreased iron content during in vitro culture and is restored with exogenous iron. Lab Invest. 1992; 66: 708–714.[Medline] [Order article via Infotrieve]
  51. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003; 102: 2670–2677.[Abstract/Free Full Text]
  52. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997; 337: 408–416.[Free Full Text]
  53. Marx JJ, van Asbeck BS. Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol. 1996; 95: 49–62.[Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
 Mol Hum ReprodHome page
S. Defrere, J.C. Lousse, R. Gonzalez-Ramos, S. Colette, J. Donnez, and A. Van Langendonckt
Potential involvement of iron in the pathogenesis of peritoneal endometriosis
Mol. Hum. Reprod., July 1, 2008; 14(7): 377 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Swaminathan, V. A. Fonseca, M. G. Alam, and S. V. Shah
The Role of Iron in Diabetes and Its Complications
Diabetes Care, July 1, 2007; 30(7): 1926 - 1933.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
L. Li and B. Frei
Iron Chelation Inhibits NF-{kappa}B-Mediated Adhesion Molecule Expression by Inhibiting p22phox Protein Expression and NADPH Oxidase Activity
Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2638 - 2643.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. L. Sullivan
Stored Iron and Vascular Reactivity
Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1532 - 1535.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
24/12/2257    most recent
01.ATV.0000147406.00871.b3v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kartikasari, A. E.R.
Right arrow Articles by Marx, J. J.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kartikasari, A. E.R.
Right arrow Articles by Marx, J. J.M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*IRON
Related Collections
Right arrow Pathophysiology

ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.